Lanreotid Viatris

Lanreotide, the active ingredient in Lanreotid Viatris, is a somatostatin analog presented as an injectable solution for subcutaneous administration. It is used to manage acromegaly and certain neuroendocrine tumors by inhibiting excess hormone secretion in adult patients.

GNH USA supplies Lanreotid Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides cold‑chain logistics to ensure product integrity during global shipment. Customers benefit from dedicated regulatory support and flexible ordering options tailored to institutional needs.

Lanreotide is a somatostatin analog used in endocrine‑related disorders.

Acromegaly: reduces excess growth hormone secretion, normalizes IGF‑1 levels, and helps control disease symptoms and tumor size. Neuroendocrine tumors: suppresses hormone secretion associated with functional neuroendocrine tumors, improving symptom control and may stabilize disease progression. Carcinoid syndrome: alleviates flushing, diarrhea and abdominal cramping by inhibiting serotonin and other vasoactive peptide release.

Lanreotide may be associated with a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site reactions: pain, erythema, or induration at the subcutaneous site. - Gastrointestinal disturbances: nausea, abdominal pain, or diarrhea. - Headache: mild to moderate intensity. - Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects: - Gallbladder disease: cholelithiasis or biliary colic. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Cardiovascular events: arrhythmias or bradycardia.

Before initiating lanreotide therapy, healthcare professionals should consider several precautionary measures. - Patient assessment: evaluate baseline hormone levels and tumor activity to determine suitability. - Diabetes monitoring: monitor blood glucose as lanreotide can worsen hyperglycemia. - Gallbladder evaluation: assess for gallstones or biliary disease prior to treatment. - Cardiac review: consider cardiac history because bradyarrhythmias have been reported. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Cytochrome P450 inducers: strong inducers may reduce lanreotide exposure; avoid concomitant use. - Somatostatin analog antagonists: may counteract therapeutic effect; avoid combination.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: lanreotide may increase glucose; adjust dosage of insulin or oral hypoglycemics. - Antiplatelet or anticoagulant drugs: monitor for increased bleeding risk due to possible platelet function changes. - Thyroid hormone replacement: monitor thyroid function tests as hormone levels may be altered.